441 related articles for article (PubMed ID: 19913918)
41. Controlled assembly of ruthenium complexes through ortho-carborane dithiolate and polysulfide ligands.
Hu J; Liu G; Jiang Q; Zhang R; Huang W; Yan H
Inorg Chem; 2010 Dec; 49(23):11199-204. PubMed ID: 21028782
[TBL] [Abstract][Full Text] [Related]
42. DNA binding, cytotoxicity, and apoptotic-inducing activity of ruthenium(II) polypyridyl complex.
Zhang P; Chen J; Liang Y
Acta Biochim Biophys Sin (Shanghai); 2010 Jul; 42(7):440-9. PubMed ID: 20705582
[TBL] [Abstract][Full Text] [Related]
43. DNA binding and topoisomerase II inhibitory activity of water-soluble ruthenium(II) and rhodium(III) complexes.
Singh SK; Joshi S; Singh AR; Saxena JK; Pandey DS
Inorg Chem; 2007 Dec; 46(25):10869-76. PubMed ID: 18001110
[TBL] [Abstract][Full Text] [Related]
44. New π-arene ruthenium(II) piano-stool complexes with nitrogen ligands.
Grau J; Noe V; Ciudad C; Prieto MJ; Font-Bardia M; Calvet T; Moreno V
J Inorg Biochem; 2012 Apr; 109():72-81. PubMed ID: 22387934
[TBL] [Abstract][Full Text] [Related]
45. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure.
Sun RW; Li CK; Ma DL; Yan JJ; Lok CN; Leung CH; Zhu N; Che CM
Chemistry; 2010 Mar; 16(10):3097-113. PubMed ID: 20162647
[TBL] [Abstract][Full Text] [Related]
46. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
47. Synthesis, molecular structure, and C-C coupling reactions of carbeneruthenium(II) complexes with C5H5Ru(=CRR') and C5Me5Ru(=CRR') as molecular units.
Braun T; Münch G; Windmüller B; Gevert O; Laubender M; Werner H
Chemistry; 2003 Jun; 9(11):2516-30. PubMed ID: 12794894
[TBL] [Abstract][Full Text] [Related]
48. Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?
Hanif M; Henke H; Meier SM; Martic S; Labib M; Kandioller W; Jakupec MA; Arion VB; Kraatz HB; Keppler BK; Hartinger CG
Inorg Chem; 2010 Sep; 49(17):7953-63. PubMed ID: 20704358
[TBL] [Abstract][Full Text] [Related]
49. In vitro transcription inhibition by ruthenium(II) polypyridyl complexes with electropositive ancillary ligands.
Gao F; Chen X; Wang JQ; Chen Y; Chao H; Ji LN
Inorg Chem; 2009 Jul; 48(13):5599-601. PubMed ID: 19505113
[TBL] [Abstract][Full Text] [Related]
50. New ruthenium(II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and cytotoxicity.
Ganeshpandian M; Loganathan R; Suresh E; Riyasdeen A; Akbarsha MA; Palaniandavar M
Dalton Trans; 2014 Jan; 43(3):1203-19. PubMed ID: 24177707
[TBL] [Abstract][Full Text] [Related]
51. Synthesis, characterization and DNA binding studies of two mixed ligand complexes of ruthenium(II).
Lawrence D; Vaidyanathan VG; Nair BU
J Inorg Biochem; 2006 Jul; 100(7):1244-51. PubMed ID: 16554091
[TBL] [Abstract][Full Text] [Related]
52. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
53. Synthesis, cellular uptake, apopotosis, cytotoxicity, cell cycle arrest, interaction with DNA and antioxidant activity of ruthenium(II) complexes.
Huang HL; Li ZZ; Liang ZH; Yao JH; Liu YJ
Eur J Med Chem; 2011 Aug; 46(8):3282-90. PubMed ID: 21570748
[TBL] [Abstract][Full Text] [Related]
54. Half-sandwich RuII-[9]aneS3 complexes with dicarboxylate ligands: synthesis, characterization and chemical behavior.
Bratsos I; Birarda G; Jedner S; Zangrando E; Alessio E
Dalton Trans; 2007 Sep; (36):4048-58. PubMed ID: 17828366
[TBL] [Abstract][Full Text] [Related]
55. Highly active neutral ruthenium(II) arene complexes: synthesis, characterization, and investigation of their anticancer properties.
Ludwig G; Kaluđerović GN; Bette M; Block M; Paschke R; Steinborn D
J Inorg Biochem; 2012 Aug; 113():77-82. PubMed ID: 22698819
[TBL] [Abstract][Full Text] [Related]
56. Cytotoxicity, cellular uptake, and DNA interactions of new monodentate ruthenium(II) complexes containing terphenyl arenes.
Bugarcic T; Nováková O; Halámiková A; Zerzánková L; Vrána O; Kaspárková J; Habtemariam A; Parsons S; Sadler PJ; Brabec V
J Med Chem; 2008 Sep; 51(17):5310-9. PubMed ID: 18702458
[TBL] [Abstract][Full Text] [Related]
57. Ruthenium(II) and ruthenium(IV) complexes containing kappa1-P-, kappa2-P,O-, and kappa3-P,N,O-iminophosphorane-phosphine ligands Ph2PCH2P[=NP(=O)(OR)2]Ph2 (R = Et, Ph): synthesis, reactivity, theoretical studies, and catalytic activity in transfer hydrogenation of cyclohexanone.
Cadierno V; Crochet P; Díez J; García-Alvarez J; García-Garrido SE; Gimeno J; García-Granda S; Rodríguez MA
Inorg Chem; 2003 May; 42(10):3293-307. PubMed ID: 12739971
[TBL] [Abstract][Full Text] [Related]
58. Synthesis, characterisation and thermal studies of ruthenium(II) carbonyl complexes of functionalised tripodal phosphine chalcogen donor ligands, [CH(3)C(CH(2)P(X)Ph(2))(3)], where X=Se, S, O.
Deb B; Sarmah BJ; Borah BJ; Dutta DK
Spectrochim Acta A Mol Biomol Spectrosc; 2009 Mar; 72(2):339-42. PubMed ID: 19019724
[TBL] [Abstract][Full Text] [Related]
59. Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes.
Liu HK; Wang F; Parkinson JA; Bella J; Sadler PJ
Chemistry; 2006 Aug; 12(23):6151-65. PubMed ID: 16807967
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and cytotoxicity of dinuclear complexes containing ruthenium(II) bipyridyl units linked by a bis(pyridylimine) ligand.
McDonnell U; Kerchoffs JM; Castineiras RP; Hicks MR; Hotze AC; Hannon MJ; Rodger A
Dalton Trans; 2008 Feb; (5):667-75. PubMed ID: 18217123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
